biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Neuramedy - NM-101 in IND preperation

<< Previous

Bullboard Posts

Next >>

Post by LOOPA441on May 22, 2022 10:10pm

366 Views

Post# 34701615

Neuramedy - NM-101 in IND preperation

Not sure if it was discussed that Neuramedy's NM-101, which will now include XB3, is currently in IND preperation.

I completely missed the section below as I was focused on the lack of upfront capital in the deal.

Believe this represents the closest XB3 technology has ever been to getting into the clinic.

Seems like a strategic way of validating the technology without dilution.

But how long will the preparation take? Does this imply that IND-Enabling studies with the technology have alread been completed? If so, why did the Neuramedy CEO state that he expects that XB3 will improve efficacy and safety?

Can someone provide clarity on this?

Thanks in advance.

About Neuramedy

Neuramedy Co., Ltd. Is a Korean biopharmaceutical company established in 2019 based on the long time research of Dr. Seung Jae Lee. The company envisions the development of disease modifying therapies for early intervention of diseases. The company focuses on developing the treatments for neurodegenerative diseases. The lead pipeline NM-101, Tomaralimab for Parkinson’s disease, is currently in IND preparation. For more information about the company, please visit www.neuramedy.com.

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec